Trial Profile
A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs DCVAC OvCa (Primary) ; Carboplatin; Gemcitabine
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 19 Jul 2021 To allow the replacement of patients who were randomized to the DCVAC/OvCa group but failed to receive at least one dose of DCVAC/OvCa and the randomization ratio was changed from 1:1 to 2.5:1 the trial protocol was amended so that an approximately equal number of patients in both groups in the primary analysis set as per results published in the Gynecologic Oncology
- 19 Jul 2021 Primary endpoint (PFS (progression free survival)) has not been met as per results published in the Gynecologic Oncology
- 19 Jul 2021 Results published in the Gynecologic Oncology